15 The study found that GLP-1 medication was associated with an 18% relative reduction in risk of developing any AMD from no AMD at baseline: 0.46% of the GLP-1 group had any AMD after 10 years, while 0.55% had any AMD in the control group
Melanin can add some natural UV protection, but it does not block UV like broad-spectrum sunscreen
The majority of the phenolics, flavanoids, and anthocyanins are antioxidants that dissolve in water
#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
